Stock exchanges & markets

Overview Watchlists

Basilea wins USD 5.4 million BARDA grant for ceftibuten-ledaborbactam antibiotic development

5. Aug 2026

(AWP Alliance News) - Basilea Pharmaceutica AG secured an additional USD 5.4 million in BARDA funding to advance its oral antibiotic ceftibuten-ledaborbactam etzadroxil for complicated urinary tract infections. Total BARDA funding awarded to date rises to USD 30.8 million.

The contract provides for up to USD 172 million in potential non-dilutive support.

http://www.globenewswire.com/newsroom/news.html?d=1001256053

Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire on August 05, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • ETF Compass

    Stock exchanges & markets

    ETFs are becoming increasingly popular. Our ETF Compass helps you maintain an overview. Filter by criteria such as asset class, region, rating, return or costs. 

    Try the ETF Compass now

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now